A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(15 sites)
United States
ULCA, Los Angeles, California UCSF, San Francisco, California University of Colorado, Aurora, Colorado Sarah Cannon Research Institute, Denver, Colorado Sarah Cannon Research Institute, Sarasota, Florida Sarah Cannon Research Institute, Nashville, Tennessee MD Anderson Cancer Center, Houston, Texas NEXT Dallas, Irving, Texas NEXT Virginia, Fairfax, Virginia Fred Hutchinson Cancer Center, Seattle, Washington China
Peking University Cancer Hospital, Beijing, Beijing Municipality Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Hunan Cancer Hospital, Changsha, Hunan Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality Zhongshan Hospital Fudan University, Shanghai, Shanghai Municipality Last updated February 2026